UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported): June 7, 2016

 

 

Protalix BioTherapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

         
Delaware   001-33357   65-0643773

(State or other jurisdiction

of incorporation)

 

  (Commission File Number)  

(IRS Employer

Identification No.)

 

 

     
2 Snunit Street   20100
Science Park, POB 455    
Carmiel, Israel    
(Address of principal executive offices)   (Zip Code)

 

Registrant's telephone number, including area code +972-4-988-9488

 

 

(Former name or former address, if changed since last report.)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 

Item 7.01. Regulation FD Disclosure

 

On June 7, 2016, Moshe Manor, the President and Chief Executive Officer of Protalix BioTherapeutics, Inc., presented a corporate overview at the Jefferies 2016 Global Healthcare Conference. A copy of the slide presentation used in Mr. Manor’s presentation is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

 

An archived webcast of the presentation is available at www.protalix.com, on the event calendar page.

 

All of the information furnished in Item 7.01 and Exhibit 99.1 hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and unless expressly set forth by specific reference in such filings, shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, whether made before or after the date hereof and regardless of any general incorporation language in such filings.

 

Item 9.01. Financial Statements and Exhibits

 

(d) Exhibits

 

99.1 Slide Presentation entitled “Protalix BioTherapeutics Corporate Update – June 2016.”

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  PROTALIX BIOTHERAPEUTICS, INC.
   
Date: June 7, 2016 By: /s/ Moshe Manor
  Name: Moshe Manor
  Title: President and Chief Executive Officer

 

 

 

 

 

 

Protalix BioTherapeutics (AMEX:PLX)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Protalix BioTherapeutics Charts.
Protalix BioTherapeutics (AMEX:PLX)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Protalix BioTherapeutics Charts.